Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 15:12:23 UTC |
---|
Update Date | 2022-03-07 02:49:17 UTC |
---|
HMDB ID | HMDB0002972 |
---|
Secondary Accession Numbers | - HMDB0062451
- HMDB02972
- HMDB62451
|
---|
Metabolite Identification |
---|
Common Name | Vitamin K1 2,3-epoxide |
---|
Description | Vitamin K1 2,3-epoxide (CAS: 25486-55-9) is a vitamin K derivative. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. Within the cell, vitamin K undergoes electron reduction to a reduced form of vitamin K (called vitamin K hydroquinone) by the enzyme vitamin K epoxide reductase (or VKOR). Another enzyme then oxidizes vitamin K hydroquinone to allow carboxylation of glutamate into gamma-carboxyglutamate (Gla). This enzyme is called the gamma-glutamyl carboxylase or the vitamin K-dependent carboxylase. The carboxylation reaction will only proceed if the carboxylase enzyme is able to oxidize vitamin K hydroquinone into vitamin K epoxide at the same time; the carboxylation and epoxidation reactions are said to be coupled reactions. Vitamin K epoxide is then re-converted into vitamin K by the vitamin K epoxide reductase. These two enzymes comprise the so-called vitamin K cycle. One of the reasons why vitamin K is rarely deficient in a human diet is because vitamin K is continually recycled in our cells. Vitamin K 2,3-epoxide is the substrate for vitamin K 2,3-epoxide reductase (VKOR) complex. Significantly increased level of serum vitamin K epoxide has been found in patients with familial multiple coagulation factor deficiency (PMID: 12384421 ). Accumulation of vitamin K1-2,3-epoxide in plasma is also a sensitive marker of the coumarin-like activity of drugs (PMID: 2401753 ). |
---|
Structure | CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\C[C@@]12O[C@]1(C)C(=O)C1=C(C=CC=C1)C2=O InChI=1S/C31H46O3/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-31-29(33)27-19-8-7-18-26(27)28(32)30(31,6)34-31/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-,30-,31+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2,3-Epoxyphytyl)menaquinone | HMDB | 2,3-Epoxy-2,3-dihydro-2-methyl-3-phytyl-1,4-naphthoquinone | HMDB | 2,3-Epoxyphylloquinone | HMDB | 1a,7a-Dihydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecenyl)-naphth[2,3-b]oxirene-2,7-dione | HMDB | Phylloquinone oxide | HMDB | Phylloquinone epoxide | HMDB | Phylloquinone-2,3-epoxide | HMDB | Vitamin K1 oxide | HMDB | Vitamin K epoxide | HMDB | Vitamin K(1) oxide | HMDB | Vitamin K1 epoxide | HMDB | 1,4-Naphthoquinone, 2,3-epoxy-2,3-dihydro-2-methyl-3-phytyl-2,3-epoxyphylloquinone | HMDB | Naphth[2,3-b]oxirene-2,7-dione, 1a,7a-dihydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecenyl)-phylloquinone oxide | HMDB | Phylloquinone, epoxide | HMDB | Vitamin K 2,3-epoxide | HMDB | Vitamin K1, epoxide | HMDB | Phylloquinone 2,3-epoxide | HMDB | Vitamin K oxide | HMDB | Vitamin K1 2,3-epoxide | HMDB |
|
---|
Chemical Formula | C31H46O3 |
---|
Average Molecular Weight | 466.706 |
---|
Monoisotopic Molecular Weight | 466.344695341 |
---|
IUPAC Name | (1aS,7aR)-1a-methyl-7a-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1aH,2H,7H,7aH-naphtho[2,3-b]oxirene-2,7-dione |
---|
Traditional Name | (1aS,7aR)-1a-methyl-7a-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphtho[2,3-b]oxirene-2,7-dione |
---|
CAS Registry Number | 85955-78-8 |
---|
SMILES | CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\C[C@@]12O[C@]1(C)C(=O)C1=C(C=CC=C1)C2=O |
---|
InChI Identifier | InChI=1S/C31H46O3/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-31-29(33)27-19-8-7-18-26(27)28(32)30(31,6)34-31/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-,30-,31+/m1/s1 |
---|
InChI Key | KUTXFBIHPWIDJQ-BTPXSFBUSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as vitamin k compounds. These are quinone lipids containing a methylated naphthoquinone ring structure, and vary in the aliphatic side chain attached at the 3-position. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Prenol lipids |
---|
Sub Class | Quinone and hydroquinone lipids |
---|
Direct Parent | Vitamin K compounds |
---|
Alternative Parents | |
---|
Substituents | - Diterpenoid
- Naphthoquinone
- Naphthalene
- Tetralin
- Quinone
- Aryl ketone
- Aryl alkyl ketone
- Benzenoid
- Ketone
- Oxacycle
- Ether
- Oxirane
- Dialkyl ether
- Organoheterocyclic compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Vitamin K1 2,3-epoxide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 10V, Negative-QTOF | splash10-014i-0000900000-34d4a26fdf7a1cd26730 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 20V, Negative-QTOF | splash10-014r-0200900000-9ed845fe28276c1a2640 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 40V, Negative-QTOF | splash10-004r-0209100000-2b233ea9a16eecb88522 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 10V, Positive-QTOF | splash10-014i-0012900000-5563789bc0b75fbe920c | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 20V, Positive-QTOF | splash10-0a4j-9730300000-4af0219041341f3904b9 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Vitamin K1 2,3-epoxide 40V, Positive-QTOF | splash10-0002-9711000000-82abc89ed052cf2ea570 | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|
General References | - Komatsu K, Kayashima N, Ariyoshi N, Shirahata A: [Vitamin K]. Nihon Rinsho. 1993 Apr;51(4):943-51. [PubMed:8483276 ]
- Hirauchi K, Sakano T, Nagaoka T, Morimoto A: Simultaneous determination of vitamin K1, vitamin K1 2,3-epoxide and menaquinone-4 in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr. 1988 Aug 19;430(1):21-9. [PubMed:2851012 ]
- McBurney A, Shearer MJ, Barkhan P: Changes in the urinary metabolites of phylloquinone (vitamin K1) in man following therapeutic anticoagulation with warfarin. Biochem Pharmacol. 1978 Feb 1;27(3):273-8. [PubMed:619911 ]
- Fregin A, Rost S, Wolz W, Krebsova A, Muller CR, Oldenburg J: Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood. 2002 Nov 1;100(9):3229-32. [PubMed:12384421 ]
- Trenk D, Wagner F, Bechtold H, Nies B, Jahnchen E: Lack of effect of cefixime on the metabolism of vitamin K1. J Clin Pharmacol. 1990 Aug;30(8):737-42. [PubMed:2401753 ]
|
---|